#### PATENT COOPERATION TREATY

#### From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis, 3(c) and 72.2)

т	٠.
I	u

SHIMIZU, Hatsushi Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki 3000847 JAPON

Date of mailing (day/month/year) 14 September 2006 (14.09.2006)	
Applicant's or agent's file reference C1-A0320Y2P	IMPORTANT NOTIFICATION
International application No. PCT/JP2004/018506	International filing date (day/month/year) 10 December 2004 (10.12.2004)
Applicant CHUGAI SE	EIYAKU KABUSHIKI KAISHA et al

1. Transmittal of the translation to the applicant.



The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

EP, KR

V

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Yoshiko Kuwahara

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70

# TRANSLATION

### PATENT COOPERATION TREATY

# **PCT**

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

		(PC I Affic	le 30 and Rule 70)					
Applicant's or agen		FOR FURTHER	ACTION	See Form PCT/IPEA/416				
International applic	ation No.	International filing d	ate (day/month/year)	Priority date (day/month/year) 12.12.2003				
	t Classification (IPC) or natio							
C07K16/2	8, C12N15/11,							
Applicant CHUGAI S	EIYAKU KABUSI	HIKI KAISH	A					
	ort is the international prelin			nternational Preliminary Examining Authority				
2. This REP	ORT consists of a total of	8	sheets, including	this cover sheet.				
3. This repo	rt is also accompanied by Al	NEXES, comprising	:					
a. 🔲	(sent to the applicant and	to the International Bi	ureau) a total of	sheets, as follows:				
	sheets of the descript	tion, claims and/or dr	awings which have been a	mended and are the basis for this report and/or le 70.16 and Section 607 of the Administrative				
				siders contain an amendment that goes beyond in item 4 of Box No. I and the Supplemental				
ъ. 🔽	(sent to the International E	Bureau only) a total of	(indicate type and number	of electronic carrier(s))				
_	•	••	•					
	related thereto, in computer Section 802 of the Administr		as indicated in the Suppler	_, containing a sequence listing and/or tables mental Box Relating to Sequence Listing (see				
4. This repo	rt contains indications relatir	ng to the following ite	ms:					
В	ox No. I Basis of the	report						
	ox No. II Priority							
⊠ в ⊠ в	ox No. III Non-establis	hment of opinion with	n regard to novelty, inventi	ve step and industrial applicability				
В	ox No. IV Lack of unit	y of invention						
$\sim$	0/12:01	atement under Article explanations support	<del>-</del>	ty, inventive step or industrial applicability;				
Box No. VI Certain documents cited								
Box No. VII Certain defects in the international application								
Box No. VIII Certain observations on the international application								
Date of submission of the demand  Date of completion of this report								
Name and mailing a	address of the IPEA/JP		Authorized officer					
Engrissile No			Telephone No					

International application No.

PCT/JP2004/018506

Bo	x No. I	Basis of the report								
1.		regard to the language, this report is based on the in- cated under this item.	ternational application in the language in which	ch it was filed, unless otherwise						
	This report is based on translations from the original language into the following which is the language of a translation furnished for the purposes of:									
		international search (Rule 12.3 and 23.1(b))								
		publication of the international application (Re	ale 12.4)							
		international preliminary examination (Rule 5:	5.2 and/or 55.3)							
2.	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):									
	$\bowtie$	the international application as originally filed/furnis	shed							
	Ш	the description:								
1		pages		as originally filed/furnished						
		pages*	received by this Authority on							
		pages*	received by this Authority on							
İ		the claims:								
		nos.		as originally filed/furnished						
		nos.*	as amended (together wit	th any statement) under Article 19						
		nos.*	received by this Authority on							
		nos.*	received by this Authority on							
		the drawings:								
		sheets		as originally filed/furnished						
		sheets*	received by this Authority on							
			received by this Authority on							
	$\boxtimes$	a sequence listing and/or any related table(s) - see S		σ						
		•		Ē·						
3.	لــا	The amendments have resulted in the cancellation of	t:	!						
		the description, pages								
				<del></del>						
		the drawings, sheets/figs								
		any table(s) related to sequence listing (specify								
4.	Ш	This report has been established as if (some of) the they have been considered to go beyond the disclosu								
		the description, pages								
		the claims, nos.								
		the drawings, sheets/figs								
		the sequence listing (specify):								
		any table(s) related to sequence listing (specify	p):	·						
*	If ite	m 4 applies, some or all of those sheets may be marke	ed "superseded."							

International application No.

			PC1/JP2004/018506					
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability								
	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:							
	the entire international application							
$\boxtimes$	claims Nos. 5-38							
becaus								
	the said international application, or th		cy examination (succifive					
		dicate particular elements below) or said claims ion could be formed (specify):						
	the claims, or said claims Nos. by the description that no meaningful c	pinion could be formed.	are so inadequately supported					
$\boxtimes$	no international search report has been	established for said claims Nos. 5-38						
	the nucleotide and/or amino acid seque Instructions in that:	ence listing does not comply with the standard p	rovided for in Annex C of the Administrative					
	the written form	has not been furnished						
		does not comply with the standard						
	the computer readable form	has not been furnished does not comply with the standard						
		Nor amino acid sequence listing, if in computer Annex C-bis of the Administrative Instructions.	r readable form only, do not comply with the					
	See Supplemental Box for further detail	ls.						

International application No.
PCT/JP2004/018506

		INTERNATIONAL FREE INTERNATIONAL FREE INTERNATIONAL FREE INTERNATIONAL FREE INTERNATIONAL FREE INTERNATIONAL F	PCT/JP2004/018506
Во	x No. 1	V Lack of unity of invention	
1.		In response to the invitation to restrict or pay additional fees the applicant has:	
		restricted the claims.	
		paid additional fees.	
		paid additional fees under protest.	
		neither restricted the claims nor paid additional fees.	
2.		This Authority found that the requirement of unity of invention is not complied with a the applicant to restrict or pay additional fees.	and chose, according to Rule 68.1, not to invite
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules	13.1, 13.2 and 13.3 is:
		complied with.	
	$\boxtimes$	not complied with for the following reasons:	
		The polynucleotides having a base	sequence
		represented by SEQ ID NOS: 1 to 65 and	the
		polypeptides expressed by said polynucl	leotides as set
		forth in claim 1 do not share a common	chemical
		structure, and the only commonality bet	tween the
		inventions set forth in the SEQ ID $\ensuremath{NOS}$	is that
		specificity is only expressed in lung of	cancer, stomach
		cancer, cancer of the colon or hepatic	cancer tissue.
		However, document 1 sets forth a c	gene which is
		specifically expressed in cancer of the	e colon and lung
		cancer (Table 2, Co column and Lu colum	nn).
		In addition, document 2 sets forth	n a gene which
		is specifically expressed in cancer of	the colon
		(Table 1).	
		In addition, document 3 sets forth	n a gene which
		is specifically expressed in hepatic ca	ncer (Table 2).
		(Continued in Supplemental Box)	
4.	Cons	equently, this report has been established in respect of the following parts of the internat	tional application:
		all parts.	
	$\boxtimes$	the parts relating to claims Nos. 1-4	

8

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/018506

			r Article 35(2) with regard to novelty, inventive step or industrial applicability; supporting such statement				
1.	Statement						
	Novelty (N)	Claims		YES			
		Claims	1-4	NO			
	Inventive step (IS)	Claims		YES			
		Claims	1-4	NO			
	Industrial applicability (IA)	Claims	1-4	YES			
		Claims		NO			

2. Citations and explanations (Rule 70.7)

Document 1: WO 02/33072 A1 (Chugai Pharmaceutical Co.,

Ltd.)

Document 2: WO 02/33073 A1 (Chugai Pharmaceutical Co.,

Ltd.)

Claims 1 to 4

The invention set forth in claims 1 to 4 lacks novelty in the light of the inventions set forth in documents 1 and 2.

Documents 1 and 2 set forth single chain polypeptides having bonding activity to a TPO receptor having two heavy chain variable regions and two light chain variable regions arranged in the order heavy chain variable region, light chain variable region, heavy chain variable region and light chain variable region with the N-terminal side as a reference point, wherein the polypeptide is bonded by linkers, and amino acids 3 to 18 are preferable as linkers, and amino acid 15 is used (document 1, page 4, line 19 to page 5, line 20; page 9, line 26 to page 13; line 27; page 68; fig. 34, document 2, page 4, line 27 to page 6, line 24; page 15, line 2 to page 16, line 28; page 31; fig. 34).

Therefore there is no discernible difference between

International application No.
PCT/JP2004/018506

Box	No. V		Reas	oned ons a	statem and exp	ent ui Ianati	nder A	rticle	35(2 ing :	) with such s	n regai	rd to ent	novelt	y, inv	enti	ve step	or in	dustrial	applicability	
	the	in	ver	nti	ons	se	t i	ort	h	in	do	cur	nen	ts	1	and	2	and	the	
	inv	ent	ior	າຣ	set	fo	rtl	ı ir	1 (	cla	ims	1	to	4.						

International application No.

	PC1/JP2004/018506									
Supplemental Box Relating to Sequence Listing										
Continuation of Box No. I, item 2:										
With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:										
a. type of material										
a sequence listing										
Lable(s) related to the sequence listing										
b. format of material in written format										
in computer readable form										
c. time of filing/furnishing										
contained in the international application as filed										
filed together with the international application in computer readable form										
furnished subsequently to this Authority for the purposes of search and/or examina	ation									
received by this Authority as an amendment* on	<del></del>									
2. In addition, in the case that more than one version or copy of a sequence listing and/or to furnished, the required statements that the information in the subsequent or additional confiled or does not go beyond the application as filed, as appropriate, were furnished.										
3. Additional comments:										
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the "superseded."	basis of the report, may be marked									

International application No.
PCT/JP2004/018506

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

Therefore being specifically expressed only in lung cancer, stomach cancer, cancer of the colon or hepatic cancer tissue cannot be described as a special technical feature within the meaning of PCT Rule 13.2.

Such being the case, the inventions according to the 65 SEQ ID NOS set forth in claims 1 to 27 are considered not as a group of inventions so linked as to form a single general inventive concept but as a group of inventions comprising 65 inventions respectively relating to 65 different polynucleotides and the polypeptides expressed by these polynucleotides.

- Document 1: SCHEURLE D. et al., Cancer gene discovery using digital differential display, Cancer Res. (2000), Vol. 60, No. 15, pages 4037 to 4043
- Document 2: Matthias P. A. E. et al., Expression of
  Metallothionein II in Intestinal Metaplasia,
  Dysplasia, and Gastric Cancer, Cancer
  Research (2000), Vol. 60, pages 1995 to 2001
- Document 3: Xu X.R. et al., Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver, Proc.

  Natl. Acad. Sci. USA. (2001), Vol. 98, No. 26, pages 4037 to 4043